REFERENCES
[1]Siddiqui U Prevalence and predictors of herbal medication use in veterans with chronic hepatitis C. J Clin
Gastroenterol. 2004 Aug;38(7):605-10. [2] Wallace SN Extraction of nutraceuticals from milk thistle: part II. Extraction
with organic solvents. Appl Biochem Biotechnol. 2003 Spring;105 -108:891-903. [3] Wallace SN Batch solvent
extraction of flavanolignans from milk thistle (Silybum marianum L. Gaertner). Phytochem Anal. 2005
Jan-Feb;16(1):7-16. [4]Duan L Silymarin extraction from milk thistle using hot water. Appl Biochem Biotechnol. 2004
Spring;113-116:559-68.[5] Lee DY, Molecular structure and stereochemistry of silybin A, silybin B, isosilybin A, and
isosilybin B, Isolated from Silybum marianum (milk thistle). J Nat Prod. 2003 Dec;66(12):1632. [6] Kim NC Complete
isolation and characterization of silybins and isosilybins from milk thistle (Silybum marianum). Org Biomol Chem.
2003 May 21;1(10):1684-9.[7] Manna SK Silymarin [MILK THISTLE] suppresses TNF-induced activation of NF-kappa
B, c-Jun N-terminal kinase, and apoptosis. J Immunol. 1999 Dec 15;163(12):6800-9. [8] Lee DG et al Gram-positive
bacteria specific properties of silybin derived from Silybum marianum [Milk Thistle]. Arch Pharm Res. 2003
Aug;26(8):597-600.[9] Soliman KF In vitro attenuation of nitric oxide production in C6 astrocyte cell culture by
various dietary compounds. Proc Soc Exp Biol Med. 1998 Sep;218(4):390-7.[10] Bialecka M. The effect of
bioflavonoids and lecithin on the course of experimental atherosclerosis in rabbits Ann Acad Med Stetin.
1997;43:41-56. [11]Zi X, Novel cancer chemopreventive effects of a flavonoid antioxidant silymarin [MILK THISTLE]:
inhibition of mRNA expression of an endogenous tumor promoter TNF alpha. Biochem Biophys Res Commun. 1997
Oct 9;239(1):334-9.[12]Tyagi A Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell
carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages. Carcinogenesis.
2004 Sep;25(9):1711-20. Epub 2004 Apr *milk thistle [13]Tyagi AK Silibinin down-regulates survivin protein and
mRNA expression and causes caspases activation and apoptosis in human bladder transitional-cell papilloma RT4
cells. Biochem Biophys Res Commun. 2003 Dec 26;312(4):1178-84.[14] Vinh PQ et al Chemopreventive effects of a
flavonoid antioxidant silymarin [MILK THISTLE] on N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder
carcinogenesis in male ICR mice. Jpn J Cancer Res. 2002 Jan;93(1):42-9. [15]Tyagi AK Synergistic anti-cancer
effects of silibinin [milk thistle extract] with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin
against human breast carcinoma MCF-7 and MDA-MB468 cells. Oncol Rep. 2004 Feb;11(2):493-9.Zi X.
Anticarcinogenic effect of a flavonoid antioxidant, silymarin [milk thistle], in human breast cancer cells MDA-MB 468:
induction of G1 arrest through an increase in Cip1/p21 concomitant with a decrease in kinase activity of
cyclin-dependent kinases and associated cyclins. Clin Cancer Res. 1998 Apr;4(4):1055-64.[17]  Kohno H et al,
Silymarin [MILK THISTLE], a naturally occurring polyphenolic antioxidant flavonoid, inhibits azoxymethane-induced
colon carcinogenesis in male F344 rats. Int J Cancer. 2002 Oct 10;101(5):461-8.[18] Yoo HG Involvement of
NF-kappaB and caspases in silibinin-induced apoptosis of endothelial cells. Int J Mol Med. 2004 Jan;13(1):81-6.[19]
Qi L, Epidermal growth factor receptor mediates silibinin [milk thistle]-induced cytotoxicity in a rat glioma cell line.
Cancer Biol Ther. 2003 Sep-Oct;2(5):526-31.[20] Chu SC Silibinin inhibits the invasion of human lung cancer cells
via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2. Mol Carcinog. 2004
Jul;40(3):143-9.[21] Ladas EJ Milk thistle: is there a role for its use as an adjunct therapy in patients with cancer? J
Altern Complement Med. 2003 Jun;9(3):411-6.[22] [Davis-Searles PR, Milk thistle and prostate cancer: differential
effects of pure flavonolignans from Silybum marianum [MILK THISTLE] on antiproliferative end points in human
prostate carcinoma cells. Cancer Res. 2005 May 15;65(10):4448-57] [23] Singh RP A cancer chemopreventive
agent silibinin [MILK THISTLE], targets mitogenic and survival signaling in prostate cancer. Mutat Res. 2004 Nov
2;555(1-2):21-32.[23] Thelen P Silibinin down-regulates prostate epithelium-derived Ets transcription factor in
LNCaP prostate cancer cells. Planta Med. 2004 May;70(5):397-400.[24] Inhibition of telomerase activity and
secretion of prostate specific antigen by silibinin [milk thistle] in prostate cancer cells. J Urol. 2004
May;171(5):1934-8. [25] Prostate cancer prevention by silibinin [milk thistle]. Curr Cancer Drug Targets. 2004
Feb;4(1):1-11 [26] A flavonoid antioxidant, silymarin [milk thistle], inhibits activation of erbB1 signaling and induces
cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145
cells. Cancer Res. 1998 May 1;58(9):1920-9. 27 Silibinin [Milk Thistle] decreases prostate-specific antigen with cell
growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer
intervention. Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7490-5. 28 Dhanalakshmi S Silibinin [MILK THISTLE]
sensitizes human prostate carcinoma DU145 cells to cisplatin- and carboplatin-induced growth inhibition and
apoptotic death. Int J Cancer. 2003 Sep 20;106(5):699-705. 29 Zi X Silibinin [MILK THISTLE] up-regulates
insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate
cancer cells Cancer Res. 2000 Oct 15;60(20):5617-20. [30] Singh RP Dietary feeding of [MILK THISTLE] silibinin
inhibits advance human prostate carcinoma growth in athymic mice and increases plasma insulin-like growth
factor-binding protein-3 levels. Cancer Res. 2002 Jun 1;62(11):3063-9. [31]Tyagi A et al, Silibinin [MILK THISTLE]
strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest,
and apoptosis. Clin Cancer Res. 2002 Nov;8(11):3512-9. [32] Tyagi A Antiproliferative and apoptotic effects of
silibinin [MILK THISTLE] in rat prostate cancer cells. Prostate. 2002 Nov 1;53(3):211-7.[33]Katiyar SK et al,
Protective effects of silymarin [milk thistle] against photocarcinogenesis in a mouse skin model. J Natl Cancer Inst.
1997 Apr 16;89(8):556-66][34] Katiyar SK. Silymarin [milk thistle] and skin cancer prevention: anti-inflammatory,
antioxidant and immunomodulatory effects (Review). Int J Oncol. 2005 Jan;26(1):169-76.[35] Silibinin prevents
ultraviolet radiation-caused skin damages in SKH-1 hairless mice via a decrease in thymine dimer positive cells and
an up-regulation of p53-p21/Cip1 in epidermis. Carcinogenesis. 2004 Aug;25(8):1459-65. Epub 2004 Mar 19. [36]A
flavonoid antioxidant, silymarin [milk thistle], affords exceptionally high protection against tumor promotion in the
SENCAR mouse skin tumorigenesis model. Cancer Res. 1999 Feb 1;59(3):622-32[36] Yanaida Y et al Dietary
silymarin [MILK THISTLE] suppresses 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in male F344 rats.
Carcinogenesis. 2002 May;23(5):787-94.[37]Silymarin [Milk thistle]: potent inhibitor of cyclic AMP
phosphodiesterase. Methods Find Exp Clin Pharmacol. 1985 Aug;7(8):409-13.][38]Crocenzi FA et al, Silibinin [Milk
thistle] prevents cholestasis-associated retrieval of the bile salt export pump, Bsep, in isolated rat hepatocyte
couplets: possible involvement of cAMP. Biochem Pharmacol. 2005 Apr 1;69(7):1113-20.]
[39] von Schonfeld J Silibinin [Milk thistle], a plant extract with antioxidant and membrane stabilizing properties,
protects exocrine pancreas from cyclosporin A toxicity. Cell Mol Life Sci. 1997 Dec;53(11-12):917-20.] [40] Maghrani
M Study of the hypoglycaemic activity of Fraxinus excelsior and Silybum marianum [Milk thistle]  in an animal model
of type 1 diabetes mellitus. J Ethnopharmacol. 2004 Apr;91(2-3):309-16. [41]  Chlopcikova S Chemoprotective effect
of plant phenolics against anthracycline-induced toxicity on rat cardiomyocytes. Part I. Silymarin [Milk thistle] and its
flavonolignans. Phytother Res. 2004 Feb;18(2):107-10. [42] Katiyar SK. Treatment of silymarin [MILK THISTLE], a
plant flavonoid, prevents ultraviolet light-induced immune suppression and oxidative stress in mouse skin. Int J
Oncol. 2002 Dec;21(6):1213-22. [43]Wilasrusmee C et al, Immunostimulatory effect of Silybum Marianum (milk
thistle) extract. Med Sci Monit. 2002 Nov;8(11):BR439-43.[44] Ferenci P et al, Randomized controlled trial of
silymarin [Milk thistle]  treatment in patients with cirrhosis of the liver. J Hepatol. 1989 Jul;9(1):105-13. [45] Arteel G
Advances in alcoholic liver disease. Best Pract Res Clin Gastroenterol. 2003 Aug;17(4):625-47.[46] Lieber CS
Silymarin [Milk thistle] retards the progression of alcohol-induced hepatic fibrosis in baboons. J Clin Gastroenterol.
2003 Oct;37(4):336-9.[47]. Dehmlow C. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective
properties of silibinin. Hepatology. 1996 Apr; 23 (4): 749-54. [48]. Wu DF The effects of silymarin [Milk thistle] on
hepatic microsomal and mitochondrial membrane fluidity in mice.  Zhongguo Zhong Yao Za Zhi. 2003
Sep;28(9):870-2. [49] Tanamly MD et al, Randomised double-blinded trial evaluating silymarin [Milk thistle]  for
chronic hepatitis C in an Egyptian village: study description and 12-month results. Dig Liver Dis. 2004
Nov;36(11):752-9. [50]Tedesco D Silymarin, a possible hepatoprotector in dairy cows: biochemical and histological
observations. J Vet Med A Physiol Pathol Clin Med. 2004 Mar;51(2):85-9.[51]  Wang MJ Silymarin [MILK THISTLE]
protects dopaminergic neurons against lipopolysaccharide-induced neurotoxicity by inhibiting microglia activation.
Eur J Neurosci. 2002 Dec;16(11):2103-12 [52] Kittur S et al, Neurotrophic and neuroprotective effects of milk thistle
(Silybum marianum) on neurons in culture. J Mol Neurosci. 2002 Jun;18(3):265-9.
[53] Hu Z, Herb-drug interactions: a literature review. Drugs. 2005;65(9):1239-82.][54]DiCenzo R Coadministration
of milk thistle and indinavir in healthy subjects. Pharmacotherapy. 2003 Jul;23(7):866-70.[55]  Giese LA. Milk thistle
and the treatment of hepatitis. Gastroenterol Nurs. 2001 Mar-Apr;24(2):95-7. [56] Saller R et al, The use of silymarin
in the treatment of liver diseases Drugs. 2001;61(14):2035-63.[57] Ferenci P. et al, Randomized controlled trial of
silymarin (milk thistle) treatment in patients with cirrhosis of the liver. J Hepatol. 1989 Jul;9(1):105-13. [58]Silymarin
inhibits T-lymphocyte function at low doses but stimulates inflammatory processes at high doses. Planta Med. 2003
Jan;69(1):44-9.[59] Jacobs BP, Milk thistle for the treatment of liver disease: a systematic review and meta-analysis.
Am J Med. 2002 Oct 15;113(6):506-15.[60] Rambaldi A. et al, Milk thistle for alcoholic and/or hepatitis B or C virus
liver diseases. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD003620.][61] Physiological responses of a natural
antioxidant flavonoid mixture, silymarin, in BALB/c mice: III. Silymarin inhibits T-lymphocyte function at low doses but
stimulates inflammatory processes at high doses. Planta Med. 2003 Jan;69(1):44-9.

[aa1] Raza SS, t al, Silymarin protects neurons from oxidative stress associated damages in focal cerebral ischemia:
a behavioral, biochemical and immunohistological study in Wistar rats. J Neurol Sci. 2011 Oct 15;309(1-2):45-54.
[aa2] Suksomboon N et al, Meta-analysis of the effect of herbal supplement on glycemic control in type 2 diabetes. J
Ethnopharmacol. 2011 Aug 5 [aa3] Kim JL,et al, Osteoblastogenesis and osteoprotection enhanced by
flavonolignan silibinin in osteoblasts and osteoclasts.J Cell Biochem. 2011 Sep 6 [aa4] Lian R, et al, Silymarin
Glyceryl Monooleate/Poloxamer 407 Liquid Crystalline Matrices: Physical Characterization and Enhanced Oral
Bioavailability. AAPS PharmSciTech. 2011 Sep 23.
Milk Thistle Reference
October 18, 2011
Discuss with your doctor before taking any alternative medicine. This article is for reference only. Do not copy nor transfer the content to other websites
nor blogs. ALL RIGHTS RESERVED 2011.
Different people may experience different side effects and benefits of a product. You are encouraged to report adverse side effects to FDA, its
website is
www.fda.gov., or report the adverse side effects to the manufacturer, you should be able to find the contact information on the label.

There are always new information. Please, send me an email (
zhion@zhion.com) to correct my mistake(s). Reasonable care has been taken in
preparing this document and the information provided herein is believed to be accurate. The information is not intended to be a substitute for
professional medical advice. It is important to seek the advice of a physician about any medical condition or symptom or the benefits and side
effects of a supplement or a drug product. Finally, please, do not transfer the article to other website. Thank you. ALL RIGHTS RESERVED.